EMT/MET reporter cell lines: Elevating biological models of metastasis



Epithelial-to-mesenchymal transition (EMT) and its reverse (MET) are physiological mechanisms implicated in cancer metastasis. To provide researchers with advanced biological models to study these phenomena, ATCC scientists used their mastery of CRISPR/Cas9 technology to create a number of gene-edited EMT and MET reporter cell lines. These reporter lines enable real-time monitoring of the transition of cells from epithelial to mesenchymal state (or the reverse) via the expression of red fluorescent protein (RFP)–tagged vimentin or green fluorescent protein (GFP)–tagged E-cadherin. This webinar will provide an overview of ATCC’s EMT/MET models and highlight the compelling transition data that was revealed in their development and validation.

Key points:

  • CRISPR/Cas9 genome-editing technology was applied to develop a number of RFP- or GFP-tagged reporter cell lines to study EMT and MET phenomena.
  • The EMT/MET reporter cell lines can be used to monitor cellular changes in real time or as a platform for drug screening.
  • In depth transition data were generated including morphology change, intrinsic reporter expression, marker expression, and invasion upon stimulation with EMT/MET agonists.


Diana Douglas

Diana Douglas, B.S.,
Senior Biologist, ATCC

Diana Douglas is a Senior Biologist at ATCC. For the last four years, she has focused her research on the development of advanced biological models via CRISPR/Cas9 gene-editing technology. Previously, Ms. Douglas worked at the Baker Institute for Animal Health at Cornell University and the Dalton Cardiovascular Research Center at the University of Missouri, where her research focused on the mechanisms of necrotic cell death in heart disease. Ms. Douglas attended Truman State University where she obtained a Bachelor of Science in Biology.